Table of Contents Author Guidelines Submit a Manuscript
Prostate Cancer
Volume 2011, Article ID 245642, 6 pages
http://dx.doi.org/10.1155/2011/245642
Research Article

The Metabolic Syndrome and Biochemical Recurrence following Radical Prostatectomy

1Karmanos Cancer Institute, Wayne State University, Detroit, MI 48201, USA
2Department of Oncology, Wayne State University, Detroit, MI 48201, USA
3Departments of Epidemiology and Environmental Health Sciences and Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI 48103, USA
4Department of Biostatistics and Research Epidemiology, Henry Ford Hospital, Detroit, MI 48310, USA
5Department of Epidemiology and Biostatistics, Case Western Reserve University, Cleveland, OH 44109, USA
6Departments of Epidemiology, Columbia University Mailman School of Public Health, New York, NY 10032, USA

Received 27 January 2011; Revised 3 July 2011; Accepted 1 August 2011

Academic Editor: Ann W. Hsing

Copyright © 2011 Jennifer M. Post et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Jemal, R. Siegel, J. Xu, and E. Ward, “Cancer statistics, 2010,” CA Cancer Journal for Clinicians, vol. 60, no. 5, pp. 277–300, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. C. R. Pound, A. W. Partin, M. A. Eisenberger, D. W. Chan, J. D. Pearson, and P. C. Walsh, “Natural history of progression after PSA elevation following radical prostatectomy,” Journal of the American Medical Association, vol. 281, no. 17, pp. 1591–1597, 1999. View at Publisher · View at Google Scholar · View at Scopus
  3. M. N. Simmons, A. J. Stephenson, and E. A. Klein, “Natural history of biochemical recurrence after radical prostatectomy: risk assessment for secondary therapy,” European Urology, vol. 51, no. 5, pp. 1175–1184, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. M. Han, A. W. Partin, M. Zahurak, S. Piantadosi, J. I. Epstein, and P. C. Walsh, “Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer,” Journal of Urology, vol. 169, no. 2, pp. 517–523, 2003. View at Publisher · View at Google Scholar · View at Scopus
  5. W. Demark-Wahnefried, N. M. Aziz, J. H. Rowland, and B. M. Pinto, “Riding the crest of the teachable moment: promoting long-term health after the diagnosis of cancer,” Journal of Clinical Oncology, vol. 23, no. 24, pp. 5814–5830, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. G. M. Reaven, “Banting lecture 1988. Role of insulin resistance in human disease,” Diabetes, vol. 37, no. 12, pp. 1595–1607, 1988. View at Google Scholar
  7. E. S. Ford, W. H. Giles, and W. H. Dietz, “Prevalence of the metabolic syndrome among US adults: findings from the Third National Health and Nutrition Examination Survey,” Journal of the American Medical Association, vol. 287, no. 3, pp. 356–359, 2002. View at Google Scholar · View at Scopus
  8. S. C. Smith Jr., L. T. Clark, R. S. Cooper et al., “Discovering the full spectrum of cardiovascular disease: Minority Health Summit 2003: report of the Obesity, Metabolic Syndrome, and Hypertension Writing Group,” Circulation, vol. 111, no. 10, pp. e134–e139, 2005. View at Google Scholar · View at Scopus
  9. A. W. Hsing, L. C. Sakoda, and S. Chua Jr., “Obesity, metabolic syndrome, and prostate cancer,” The American journal of clinical nutrition, vol. 86, no. 3, pp. s843–s857, 2007. View at Google Scholar · View at Scopus
  10. J. L. Beebe-Dimmer, R. L. Dunn, A. V. Sarma, J. E. Montie, and K. A. Cooney, “Features of the metabolic syndrome and prostate cancer in African-American men,” Cancer, vol. 109, no. 5, pp. 875–881, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. L. L. Håheim, T. F. Wisløff, I. Holme, and P. Nafstad, “Metabolic syndrome predicts prostate cancer in a cohort of middle-aged Norwegian men followed for 27 years,” American Journal of Epidemiology, vol. 164, no. 8, pp. 769–774, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. P. Tuohimaa, L. Tenkanen, H. Syvälä et al., “Interaction of factors related to the metabolic syndrome and vitamin D on risk of prostate cancer,” Cancer Epidemiology Biomarkers and Prevention, vol. 16, no. 2, pp. 302–307, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. J. L. Beebe-Dimmer, N. L. Nock, C. Neslund-Dudas et al., “Racial differences in risk of prostate cancer associated with metabolic syndrome,” Urology, vol. 74, no. 1, pp. 185–190, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. B. A. Rybicki, C. Neslund-Dudas, N. L. Nock et al., “Prostate cancer risk from occupational exposure to polycyclic aromatic hydrocarbons interacting with the GSTP1 Ile105Val polymorphism,” Cancer Detection and Prevention, vol. 30, no. 5, pp. 412–422, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. J. I. Cleeman, “Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III),” Journal of the American Medical Association, vol. 285, no. 19, pp. 2486–2497, 2001. View at Google Scholar · View at Scopus
  16. A. M. Cronin, G. Godoy, and A. J. Vickers, “Definition of biochemical recurrence after radical prostatectomy does not substantially impact prognostic factor estimates,” Journal of Urology, vol. 183, no. 3, pp. 984–989, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. A. W. Partin and J. E. Oesterling, “The clinical usefulness of prostate specific antigen: update 1994,” Journal of Urology, vol. 152, no. 5, part 1, pp. 1358–1368, 1994. View at Google Scholar · View at Scopus
  18. R. P. Wildman, P. Muntner, K. Reynolds et al., “The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the US population (NHANES 1999–2004),” Archives of Internal Medicine, vol. 168, no. 15, pp. 1617–1624, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. S. J. Freedland, C. L. Amling, F. Dorey et al., “Race as an outcome predictor after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database,” Urology, vol. 60, no. 4, pp. 670–674, 2002. View at Publisher · View at Google Scholar · View at Scopus
  20. R. J. Hamilton, W. J. Aronson, J. C. Presti Jr. et al., “Race, biochemical disease recurrence, and prostate-specific antigen doubling time after radical prostatectomy: results from the SEARCH database,” Cancer, vol. 110, no. 10, pp. 2202–2209, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. J. Hammarsten and B. Högstedt, “Clinical, haemodynamic, anthropometric, metabolic and insulin profile of men with high-stage and high-grade clinical prostate cancer,” Blood Pressure, vol. 13, no. 1, pp. 47–55, 2004. View at Publisher · View at Google Scholar · View at Scopus
  22. A. L. Fitzpatrick, J. R. Daling, C. D. Furberg, R. A. Kronmal, and J. L. Weissfeld, “Hypertension, heart rate, use of antihypertensives, and incident prostate cancer,” Annals of Epidemiology, vol. 11, no. 8, pp. 534–542, 2001. View at Publisher · View at Google Scholar · View at Scopus
  23. C. Rodriguez, E. J. Jacobs, A. Deka et al., “Use of blood-pressure-lowering medication and risk of prostate cancer in the Cancer Prevention Study II Nutrition Cohort,” Cancer Causes and Control, vol. 20, no. 5, pp. 671–679, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. R. M. Touyz, “Reactive oxygen species, vascular oxidative stress, and redox signaling in hypertension: what is the clinical significance?” Hypertension, vol. 44, no. 3, pp. 248–252, 2004. View at Publisher · View at Google Scholar · View at Scopus
  25. W. D. Hall, L. T. Clark, N. K. Wenger et al., “The metabolic syndrome in African Americans: a review,” Ethnicity and Disease, vol. 13, no. 4, pp. 414–427, 2003. View at Google Scholar · View at Scopus
  26. C. L. Amling, M. L. Blute, E. J. Bergstralh, T. M. Seay, J. Slezak, and H. Zincke, “Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years,” Journal of Urology, vol. 164, no. 1, pp. 101–105, 2000. View at Google Scholar · View at Scopus